Lung Cancer
We recommend
Change in Mutation Characteristics of NSCLC Detected by Liquid Biopsy – Case Study
Due to changes in mutations during the progression of metastatic non-small cell lung cancer (NSCLC) or to assess treatment response, liquid biopsy is essential for monitoring, as its results can affect the selection of targeted therapy. American authors present the case of a patient with advanced NSCLC initially treated with alectinib due to positive ALK gene rearrangement, whose therapy was switched to sotorasib after disease progression and the finding of the KRAS oncogene G12C mutation in a liquid biopsy.
Sotorasib in the Treatment of a Patient with NSCLC and DIC – A Case Report
Sotorasib is the first clinically used inhibitor of the KRAS oncogene with the G12C mutation. Its…
Treatment with Osimertinib in Patients with NSCLC After Disease Progression on Previous Therapy – Case Study
We present a case study of a patient with non-small cell lung cancer (NSCLC) with a proven…
Articles on this topic
Osimertinib in the Treatment of Patients with NSCLC with Secondary EGFR T790M Mutation – Case Study
Non-small cell lung cancer (NSCLC) is a genetically heterogeneous disease. Individualization…
Subscribe
Most read on this topic
Journal on this topic
Related topic
Most read on this topic
- Osimertinib in the Treatment of Patients with NSCLC with Secondary EGFR T790M Mutation – Case Study
- Treatment with Osimertinib in Patients with NSCLC After Disease Progression on Previous Therapy – Case Study
- Sotorasib in the Treatment of a Patient with NSCLC and DIC – A Case Report
- Change in Mutation Characteristics of NSCLC Detected by Liquid Biopsy – Case Study
Journal on this topic
Related topic